Today PHARMAC released a proposal to fund Kadcyla (trastuzumab emtansine, T-DM1) for women with advanced HER2 positive
‘This is fantastic news for these women,’ said Libby Burgess, Chair of the Breast Cancer Aotearoa Coalition (BCAC).
‘This is one of the drugs that Metavivors petitioned for and marched to parliament about last year. It is a proven
treatment that can extend the lives of these women with fewer side effects than currently available drugs.’
‘To access Kadcyla at the moment, women must pay $9,000 per month’, said Libby, ‘and this puts it beyond the reach of
most New Zealanders.’
About 20% of women with advanced breast cancer have the HER2 positive sub-type and will benefit from the decision to
Libby and other BCAC Committee members Emma Crowley and Louise Malone, along with breast cancer specialist Sarah Barton,
had just finished presenting to the Health Select Committee when they heard the news.
‘There are still drugs for other sub-types of breast cancer that need to be funded’, said Emma. ‘Today we made the case
to the Health Select Committee to bring New Zealand’s medicines budget up to a level that would enable us to have the
kind of cancer care that women in other counties enjoy.’
BCAC’s petition to the Committee called for funding for all of the drugs recommended for advanced breast cancer in the
Today the Health Select Committee also heard submissions on petitions from patient advocacy groups representing lung and
ovarian cancer, myeloma, leukemia and the rare disorders Spinal Muscular Atrophy (SMA) and Pompe disease. All described
the needless suffering imposed by New Zealand’s poor access to modern medicines for these conditions. All called for an
overhaul of PHARMAC and a substantial increase in the medicines budget to bring it into line with other OECD countries.
‘We need to at least triple the medicines budget if New Zealand is to approach the OECD average’, says BCAC Committee
member Louise Malone. ‘Only then can we have a chance to reduce our appalling breast cancer death rate’.